Click for best price
Raibizumab Biosimilars Market Size, Share 2022
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
This report contains market size and forecasts of Raibizumab Biosimilars in global, including the following market information:
Global Raibizumab Biosimilars Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Raibizumab Biosimilars Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Raibizumab Biosimilars companies in 2021 (%)
The global Raibizumab Biosimilars market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
AMD Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Raibizumab Biosimilars include Roche, Novartis, Genentech, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen and PlantForm, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Raibizumab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Raibizumab Biosimilars Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Raibizumab Biosimilars Market Segment Percentages, by Type, 2021 (%)
AMD
CNV
DME
Global Raibizumab Biosimilars Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Raibizumab Biosimilars Market Segment Percentages, by Application, 2021 (%)
ARMD
Diabetic Retinopathy
Macular Edema
Global Raibizumab Biosimilars Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Raibizumab Biosimilars Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Raibizumab Biosimilars revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Raibizumab Biosimilars revenues share in global market, 2021 (%)
Key companies Raibizumab Biosimilars sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Raibizumab Biosimilars sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Novartis
Genentech
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius
| Report Attributes |
Report Details |
| Report Title |
Raibizumab Biosimilars Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
124 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Raibizumab Biosimilars Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Raibizumab Biosimilars Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Raibizumab Biosimilars Overall Market Size
2.1 Global Raibizumab Biosimilars Market Size: 2021 VS 2028
2.2 Global Raibizumab Biosimilars Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Raibizumab Biosimilars Sales: 2017-2028
3 Company Landscape
3.1 Top Raibizumab Biosimilars Players in Global Market
3.2 Top Global Raibizumab Biosimilars Companies Ranked by Revenue
3.3 Global Raibizumab Biosimilars Revenue by Companies
3.4 Global Raibizumab Biosimilars Sales by Companies
3.5 Global Raibizumab Biosimilars Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Raibizumab Biosimilars Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Raibizumab Biosimilars Product Type
3.8 Tier 1, Tier 2 and Tier 3 Raibizumab Biosimilars Players in Global Market
3.8.1 List of Global Tier 1 Raibizumab Biosimilars Companies
3.8.2 List of Global Tier 2 and Tier 3 Raibizumab Biosimilars Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Raibizumab Biosimilars Market Size Markets, 2021 & 2028
4.1.2 AMD
4.1.3 CNV
4.1.4 DME
4.2 By Type - Global Raibizumab Biosimilars Revenue & Forecasts
4.2.1 By Type - Global Raibizumab Biosimilars Revenue, 2017-2022
4.2.2 By Type - Global Raibizumab Biosimilars Revenue, 2023-2028
4.2.3 By Type - Global Raibizumab Biosimilars Revenue Market Share, 2017-2028
4.3 By Type - Global Raibizumab Biosimilars Sales & Forecasts
4.3.1 By Type - Global Raibizumab Biosimilars Sales, 2017-2022
4.3.2 By Type - Global Raibizumab Biosimilars Sales, 2023-2028
4.3.3 By Type - Global Raibizumab Biosimilars Sales Market Share, 2017-2028
4.4 By Type - Global Raibizumab Biosimilars Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Raibizumab Biosimilars Market Size, 2021 & 2028
5.1.2 ARMD
5.1.3 Diabetic Retinopathy
5.1.4 Macular Edema
5.2 By Application - Global Raibizumab Biosimilars Revenue & Forecasts
5.2.1 By Application - Global Raibizumab Biosimilars Revenue, 2017-2022
5.2.2 By Application - Global Raibizumab Biosimilars Revenue, 2023-2028
5.2.3 By Application - Global Raibizumab Biosimilars Revenue Market Share, 2017-2028
5.3 By Application - Global Raibizumab Biosimilars Sales & Forecasts
5.3.1 By Application - Global Raibizumab Biosimilars Sales, 2017-2022
5.3.2 By Application - Global Raibizumab Biosimilars Sales, 2023-2028
5.3.3 By Application - Global Raibizumab Biosimilars Sales Market Share, 2017-2028
5.4 By Application - Global Raibizumab Biosimilars Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Raibizumab Biosimilars Market Size, 2021 & 2028
6.2 By Region - Global Raibizumab Biosimilars Revenue & Forecasts
6.2.1 By Region - Global Raibizumab Biosimilars Revenue, 2017-2022
6.2.2 By Region - Global Raibizumab Biosimilars Revenue, 2023-2028
6.2.3 By Region - Global Raibizumab Biosimilars Revenue Market Share, 2017-2028
6.3 By Region - Global Raibizumab Biosimilars Sales & Forecasts
6.3.1 By Region - Global Raibizumab Biosimilars Sales, 2017-2022
6.3.2 By Region - Global Raibizumab Biosimilars Sales, 2023-2028
6.3.3 By Region - Global Raibizumab Biosimilars Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Raibizumab Biosimilars Revenue, 2017-2028
6.4.2 By Country - North America Raibizumab Biosimilars Sales, 2017-2028
6.4.3 US Raibizumab Biosimilars Market Size, 2017-2028
6.4.4 Canada Raibizumab Biosimilars Market Size, 2017-2028
6.4.5 Mexico Raibizumab Biosimilars Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Raibizumab Biosimilars Revenue, 2017-2028
6.5.2 By Country - Europe Raibizumab Biosimilars Sales, 2017-2028
6.5.3 Germany Raibizumab Biosimilars Market Size, 2017-2028
6.5.4 France Raibizumab Biosimilars Market Size, 2017-2028
6.5.5 U.K. Raibizumab Biosimilars Market Size, 2017-2028
6.5.6 Italy Raibizumab Biosimilars Market Size, 2017-2028
6.5.7 Russia Raibizumab Biosimilars Market Size, 2017-2028
6.5.8 Nordic Countries Raibizumab Biosimilars Market Size, 2017-2028
6.5.9 Benelux Raibizumab Biosimilars Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Raibizumab Biosimilars Revenue, 2017-2028
6.6.2 By Region - Asia Raibizumab Biosimilars Sales, 2017-2028
6.6.3 China Raibizumab Biosimilars Market Size, 2017-2028
6.6.4 Japan Raibizumab Biosimilars Market Size, 2017-2028
6.6.5 South Korea Raibizumab Biosimilars Market Size, 2017-2028
6.6.6 Southeast Asia Raibizumab Biosimilars Market Size, 2017-2028
6.6.7 India Raibizumab Biosimilars Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Raibizumab Biosimilars Revenue, 2017-2028
6.7.2 By Country - South America Raibizumab Biosimilars Sales, 2017-2028
6.7.3 Brazil Raibizumab Biosimilars Market Size, 2017-2028
6.7.4 Argentina Raibizumab Biosimilars Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Raibizumab Biosimilars Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Raibizumab Biosimilars Sales, 2017-2028
6.8.3 Turkey Raibizumab Biosimilars Market Size, 2017-2028
6.8.4 Israel Raibizumab Biosimilars Market Size, 2017-2028
6.8.5 Saudi Arabia Raibizumab Biosimilars Market Size, 2017-2028
6.8.6 UAE Raibizumab Biosimilars Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Roche
7.1.1 Roche Corporate Summary
7.1.2 Roche Business Overview
7.1.3 Roche Raibizumab Biosimilars Major Product Offerings
7.1.4 Roche Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.1.5 Roche Key News
7.2 Novartis
7.2.1 Novartis Corporate Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Raibizumab Biosimilars Major Product Offerings
7.2.4 Novartis Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.2.5 Novartis Key News
7.3 Genentech
7.3.1 Genentech Corporate Summary
7.3.2 Genentech Business Overview
7.3.3 Genentech Raibizumab Biosimilars Major Product Offerings
7.3.4 Genentech Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.3.5 Genentech Key News
7.4 Pfizer
7.4.1 Pfizer Corporate Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Raibizumab Biosimilars Major Product Offerings
7.4.4 Pfizer Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.4.5 Pfizer Key News
7.5 Sartorius
7.5.1 Sartorius Corporate Summary
7.5.2 Sartorius Business Overview
7.5.3 Sartorius Raibizumab Biosimilars Major Product Offerings
7.5.4 Sartorius Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.5.5 Sartorius Key News
7.6 Eli Lilly
7.6.1 Eli Lilly Corporate Summary
7.6.2 Eli Lilly Business Overview
7.6.3 Eli Lilly Raibizumab Biosimilars Major Product Offerings
7.6.4 Eli Lilly Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.6.5 Eli Lilly Key News
7.7 Bayer
7.7.1 Bayer Corporate Summary
7.7.2 Bayer Business Overview
7.7.3 Bayer Raibizumab Biosimilars Major Product Offerings
7.7.4 Bayer Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.7.5 Bayer Key News
7.8 Amgen
7.8.1 Amgen Corporate Summary
7.8.2 Amgen Business Overview
7.8.3 Amgen Raibizumab Biosimilars Major Product Offerings
7.8.4 Amgen Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.8.5 Amgen Key News
7.9 PlantForm
7.9.1 PlantForm Corporate Summary
7.9.2 PlantForm Business Overview
7.9.3 PlantForm Raibizumab Biosimilars Major Product Offerings
7.9.4 PlantForm Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.9.5 PlantForm Key News
7.10 PharmaPraxis
7.10.1 PharmaPraxis Corporate Summary
7.10.2 PharmaPraxis Business Overview
7.10.3 PharmaPraxis Raibizumab Biosimilars Major Product Offerings
7.10.4 PharmaPraxis Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.10.5 PharmaPraxis Key News
7.11 Samsung Bioepis
7.11.1 Samsung Bioepis Corporate Summary
7.11.2 Samsung Bioepis Raibizumab Biosimilars Business Overview
7.11.3 Samsung Bioepis Raibizumab Biosimilars Major Product Offerings
7.11.4 Samsung Bioepis Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.11.5 Samsung Bioepis Key News
7.12 Centus
7.12.1 Centus Corporate Summary
7.12.2 Centus Raibizumab Biosimilars Business Overview
7.12.3 Centus Raibizumab Biosimilars Major Product Offerings
7.12.4 Centus Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.12.5 Centus Key News
7.13 Cadila Pharmaceuticals
7.13.1 Cadila Pharmaceuticals Corporate Summary
7.13.2 Cadila Pharmaceuticals Raibizumab Biosimilars Business Overview
7.13.3 Cadila Pharmaceuticals Raibizumab Biosimilars Major Product Offerings
7.13.4 Cadila Pharmaceuticals Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.13.5 Cadila Pharmaceuticals Key News
7.14 Dr Reddy's
7.14.1 Dr Reddy's Corporate Summary
7.14.2 Dr Reddy's Business Overview
7.14.3 Dr Reddy's Raibizumab Biosimilars Major Product Offerings
7.14.4 Dr Reddy's Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.14.5 Dr Reddy's Key News
7.15 Aurobindo Pharma
7.15.1 Aurobindo Pharma Corporate Summary
7.15.2 Aurobindo Pharma Business Overview
7.15.3 Aurobindo Pharma Raibizumab Biosimilars Major Product Offerings
7.15.4 Aurobindo Pharma Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.15.5 Aurobindo Pharma Key News
7.16 Biocad
7.16.1 Biocad Corporate Summary
7.16.2 Biocad Business Overview
7.16.3 Biocad Raibizumab Biosimilars Major Product Offerings
7.16.4 Biocad Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.16.5 Biocad Key News
7.17 MAbxience
7.17.1 MAbxience Corporate Summary
7.17.2 MAbxience Business Overview
7.17.3 MAbxience Raibizumab Biosimilars Major Product Offerings
7.17.4 MAbxience Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.17.5 MAbxience Key News
7.18 Hetero
7.18.1 Hetero Corporate Summary
7.18.2 Hetero Business Overview
7.18.3 Hetero Raibizumab Biosimilars Major Product Offerings
7.18.4 Hetero Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.18.5 Hetero Key News
7.19 Biocon
7.19.1 Biocon Corporate Summary
7.19.2 Biocon Business Overview
7.19.3 Biocon Raibizumab Biosimilars Major Product Offerings
7.19.4 Biocon Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.19.5 Biocon Key News
7.20 Kirin Biologics
7.20.1 Kirin Biologics Corporate Summary
7.20.2 Kirin Biologics Business Overview
7.20.3 Kirin Biologics Raibizumab Biosimilars Major Product Offerings
7.20.4 Kirin Biologics Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.20.5 Kirin Biologics Key News
7.21 Mylan
7.21.1 Mylan Corporate Summary
7.21.2 Mylan Business Overview
7.21.3 Mylan Raibizumab Biosimilars Major Product Offerings
7.21.4 Mylan Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.21.5 Mylan Key News
7.22 BeiGene
7.22.1 BeiGene Corporate Summary
7.22.2 BeiGene Business Overview
7.22.3 BeiGene Raibizumab Biosimilars Major Product Offerings
7.22.4 BeiGene Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.22.5 BeiGene Key News
7.23 Innovent
7.23.1 Innovent Corporate Summary
7.23.2 Innovent Business Overview
7.23.3 Innovent Raibizumab Biosimilars Major Product Offerings
7.23.4 Innovent Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.23.5 Innovent Key News
7.24 Qilu Pharmaceutical
7.24.1 Qilu Pharmaceutical Corporate Summary
7.24.2 Qilu Pharmaceutical Business Overview
7.24.3 Qilu Pharmaceutical Raibizumab Biosimilars Major Product Offerings
7.24.4 Qilu Pharmaceutical Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.24.5 Qilu Pharmaceutical Key News
7.25 Hengrui Pharmaceuticals
7.25.1 Hengrui Pharmaceuticals Corporate Summary
7.25.2 Hengrui Pharmaceuticals Business Overview
7.25.3 Hengrui Pharmaceuticals Raibizumab Biosimilars Major Product Offerings
7.25.4 Hengrui Pharmaceuticals Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.25.5 Hengrui Pharmaceuticals Key News
7.26 Hisun Pharmaceutical
7.26.1 Hisun Pharmaceutical Corporate Summary
7.26.2 Hisun Pharmaceutical Business Overview
7.26.3 Hisun Pharmaceutical Raibizumab Biosimilars Major Product Offerings
7.26.4 Hisun Pharmaceutical Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.26.5 Hisun Pharmaceutical Key News
7.27 TOT BIOPHARM
7.27.1 TOT BIOPHARM Corporate Summary
7.27.2 TOT BIOPHARM Business Overview
7.27.3 TOT BIOPHARM Raibizumab Biosimilars Major Product Offerings
7.27.4 TOT BIOPHARM Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.27.5 TOT BIOPHARM Key News
7.28 Luye Pharmaceutical
7.28.1 Luye Pharmaceutical Corporate Summary
7.28.2 Luye Pharmaceutical Business Overview
7.28.3 Luye Pharmaceutical Raibizumab Biosimilars Major Product Offerings
7.28.4 Luye Pharmaceutical Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.28.5 Luye Pharmaceutical Key News
7.29 Henlius
7.29.1 Henlius Corporate Summary
7.29.2 Henlius Business Overview
7.29.3 Henlius Raibizumab Biosimilars Major Product Offerings
7.29.4 Henlius Raibizumab Biosimilars Sales and Revenue in Global (2017-2022)
7.29.5 Henlius Key News
8 Global Raibizumab Biosimilars Production Capacity, Analysis
8.1 Global Raibizumab Biosimilars Production Capacity, 2017-2028
8.2 Raibizumab Biosimilars Production Capacity of Key Manufacturers in Global Market
8.3 Global Raibizumab Biosimilars Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Raibizumab Biosimilars Supply Chain Analysis
10.1 Raibizumab Biosimilars Industry Value Chain
10.2 Raibizumab Biosimilars Upstream Market
10.3 Raibizumab Biosimilars Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Raibizumab Biosimilars Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Raibizumab Biosimilars in Global Market
Table 2. Top Raibizumab Biosimilars Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Raibizumab Biosimilars Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Raibizumab Biosimilars Revenue Share by Companies, 2017-2022
Table 5. Global Raibizumab Biosimilars Sales by Companies, (K Units), 2017-2022
Table 6. Global Raibizumab Biosimilars Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Raibizumab Biosimilars Price (2017-2022) & (K USD/Unit)
Table 8. Global Manufacturers Raibizumab Biosimilars Product Type
Table 9. List of Global Tier 1 Raibizumab Biosimilars Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Raibizumab Biosimilars Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Raibizumab Biosimilars Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Raibizumab Biosimilars Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Raibizumab Biosimilars Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Raibizumab Biosimilars Sales (K Units), 2017-2022
Table 15. By Type - Global Raibizumab Biosimilars Sales (K Units), 2023-2028
Table 16. By Application ? Global Raibizumab Biosimilars Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Raibizumab Biosimilars Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Raibizumab Biosimilars Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Raibizumab Biosimilars Sales (K Units), 2017-2022
Table 20. By Application - Global Raibizumab Biosimilars Sales (K Units), 2023-2028
Table 21. By Region ? Global Raibizumab Biosimilars Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Raibizumab Biosimilars Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Raibizumab Biosimilars Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Raibizumab Biosimilars Sales (K Units), 2017-2022
Table 25. By Region - Global Raibizumab Biosimilars Sales (K Units), 2023-2028
Table 26. By Country - North America Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Raibizumab Biosimilars Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Raibizumab Biosimilars Sales, (K Units), 2017-2022
Table 29. By Country - North America Raibizumab Biosimilars Sales, (K Units), 2023-2028
Table 30. By Country - Europe Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Raibizumab Biosimilars Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Raibizumab Biosimilars Sales, (K Units), 2017-2022
Table 33. By Country - Europe Raibizumab Biosimilars Sales, (K Units), 2023-2028
Table 34. By Region - Asia Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Raibizumab Biosimilars Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Raibizumab Biosimilars Sales, (K Units), 2017-2022
Table 37. By Region - Asia Raibizumab Biosimilars Sales, (K Units), 2023-2028
Table 38. By Country - South America Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Raibizumab Biosimilars Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Raibizumab Biosimilars Sales, (K Units), 2017-2022
Table 41. By Country - South America Raibizumab Biosimilars Sales, (K Units), 2023-2028
Table 42. By Country - Middle East & Africa Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Raibizumab Biosimilars Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Raibizumab Biosimilars Sales, (K Units), 2017-2022
Table 45. By Country - Middle East & Africa Raibizumab Biosimilars Sales, (K Units), 2023-2028
Table 46. Roche Corporate Summary
Table 47. Roche Raibizumab Biosimilars Product Offerings
Table 48. Roche Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 49. Novartis Corporate Summary
Table 50. Novartis Raibizumab Biosimilars Product Offerings
Table 51. Novartis Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 52. Genentech Corporate Summary
Table 53. Genentech Raibizumab Biosimilars Product Offerings
Table 54. Genentech Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 55. Pfizer Corporate Summary
Table 56. Pfizer Raibizumab Biosimilars Product Offerings
Table 57. Pfizer Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 58. Sartorius Corporate Summary
Table 59. Sartorius Raibizumab Biosimilars Product Offerings
Table 60. Sartorius Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 61. Eli Lilly Corporate Summary
Table 62. Eli Lilly Raibizumab Biosimilars Product Offerings
Table 63. Eli Lilly Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 64. Bayer Corporate Summary
Table 65. Bayer Raibizumab Biosimilars Product Offerings
Table 66. Bayer Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 67. Amgen Corporate Summary
Table 68. Amgen Raibizumab Biosimilars Product Offerings
Table 69. Amgen Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 70. PlantForm Corporate Summary
Table 71. PlantForm Raibizumab Biosimilars Product Offerings
Table 72. PlantForm Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 73. PharmaPraxis Corporate Summary
Table 74. PharmaPraxis Raibizumab Biosimilars Product Offerings
Table 75. PharmaPraxis Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 76. Samsung Bioepis Corporate Summary
Table 77. Samsung Bioepis Raibizumab Biosimilars Product Offerings
Table 78. Samsung Bioepis Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 79. Centus Corporate Summary
Table 80. Centus Raibizumab Biosimilars Product Offerings
Table 81. Centus Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 82. Cadila Pharmaceuticals Corporate Summary
Table 83. Cadila Pharmaceuticals Raibizumab Biosimilars Product Offerings
Table 84. Cadila Pharmaceuticals Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 85. Dr Reddy's Corporate Summary
Table 86. Dr Reddy's Raibizumab Biosimilars Product Offerings
Table 87. Dr Reddy's Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 88. Aurobindo Pharma Corporate Summary
Table 89. Aurobindo Pharma Raibizumab Biosimilars Product Offerings
Table 90. Aurobindo Pharma Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 91. Biocad Corporate Summary
Table 92. Biocad Raibizumab Biosimilars Product Offerings
Table 93. Biocad Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 94. MAbxience Corporate Summary
Table 95. MAbxience Raibizumab Biosimilars Product Offerings
Table 96. MAbxience Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 97. Hetero Corporate Summary
Table 98. Hetero Raibizumab Biosimilars Product Offerings
Table 99. Hetero Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 100. Biocon Corporate Summary
Table 101. Biocon Raibizumab Biosimilars Product Offerings
Table 102. Biocon Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 103. Kirin Biologics Corporate Summary
Table 104. Kirin Biologics Raibizumab Biosimilars Product Offerings
Table 105. Kirin Biologics Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 106. Mylan Corporate Summary
Table 107. Mylan Raibizumab Biosimilars Product Offerings
Table 108. Mylan Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 109. BeiGene Corporate Summary
Table 110. BeiGene Raibizumab Biosimilars Product Offerings
Table 111. BeiGene Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 112. Innovent Corporate Summary
Table 113. Innovent Raibizumab Biosimilars Product Offerings
Table 114. Innovent Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 115. Qilu Pharmaceutical Corporate Summary
Table 116. Qilu Pharmaceutical Raibizumab Biosimilars Product Offerings
Table 117. Qilu Pharmaceutical Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 118. Hengrui Pharmaceuticals Corporate Summary
Table 119. Hengrui Pharmaceuticals Raibizumab Biosimilars Product Offerings
Table 120. Hengrui Pharmaceuticals Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 121. Hisun Pharmaceutical Corporate Summary
Table 122. Hisun Pharmaceutical Raibizumab Biosimilars Product Offerings
Table 123. Hisun Pharmaceutical Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 124. TOT BIOPHARM Corporate Summary
Table 125. TOT BIOPHARM Raibizumab Biosimilars Product Offerings
Table 126. TOT BIOPHARM Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 127. Luye Pharmaceutical Corporate Summary
Table 128. Luye Pharmaceutical Raibizumab Biosimilars Product Offerings
Table 129. Luye Pharmaceutical Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 130. Henlius Corporate Summary
Table 131. Henlius Raibizumab Biosimilars Product Offerings
Table 132. Henlius Raibizumab Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 133. Raibizumab Biosimilars Production Capacity (K Units) of Key Manufacturers in Global Market, 2020-2022 (K Units)
Table 134. Global Raibizumab Biosimilars Capacity Market Share of Key Manufacturers, 2020-2022
Table 135. Global Raibizumab Biosimilars Production by Region, 2017-2022 (K Units)
Table 136. Global Raibizumab Biosimilars Production by Region, 2023-2028 (K Units)
Table 137. Raibizumab Biosimilars Market Opportunities & Trends in Global Market
Table 138. Raibizumab Biosimilars Market Drivers in Global Market
Table 139. Raibizumab Biosimilars Market Restraints in Global Market
Table 140. Raibizumab Biosimilars Raw Materials
Table 141. Raibizumab Biosimilars Raw Materials Suppliers in Global Market
Table 142. Typical Raibizumab Biosimilars Downstream
Table 143. Raibizumab Biosimilars Downstream Clients in Global Market
Table 144. Raibizumab Biosimilars Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Raibizumab Biosimilars Segment by Type
Figure 2. Raibizumab Biosimilars Segment by Application
Figure 3. Global Raibizumab Biosimilars Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Raibizumab Biosimilars Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Raibizumab Biosimilars Revenue, 2017-2028 (US$, Mn)
Figure 7. Raibizumab Biosimilars Sales in Global Market: 2017-2028 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Raibizumab Biosimilars Revenue in 2021
Figure 9. By Type - Global Raibizumab Biosimilars Sales Market Share, 2017-2028
Figure 10. By Type - Global Raibizumab Biosimilars Revenue Market Share, 2017-2028
Figure 11. By Type - Global Raibizumab Biosimilars Price (K USD/Unit), 2017-2028
Figure 12. By Application - Global Raibizumab Biosimilars Sales Market Share, 2017-2028
Figure 13. By Application - Global Raibizumab Biosimilars Revenue Market Share, 2017-2028
Figure 14. By Application - Global Raibizumab Biosimilars Price (K USD/Unit), 2017-2028
Figure 15. By Region - Global Raibizumab Biosimilars Sales Market Share, 2017-2028
Figure 16. By Region - Global Raibizumab Biosimilars Revenue Market Share, 2017-2028
Figure 17. By Country - North America Raibizumab Biosimilars Revenue Market Share, 2017-2028
Figure 18. By Country - North America Raibizumab Biosimilars Sales Market Share, 2017-2028
Figure 19. US Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Raibizumab Biosimilars Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Raibizumab Biosimilars Sales Market Share, 2017-2028
Figure 24. Germany Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 25. France Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Raibizumab Biosimilars Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Raibizumab Biosimilars Sales Market Share, 2017-2028
Figure 33. China Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 37. India Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Raibizumab Biosimilars Revenue Market Share, 2017-2028
Figure 39. By Country - South America Raibizumab Biosimilars Sales Market Share, 2017-2028
Figure 40. Brazil Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Raibizumab Biosimilars Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Raibizumab Biosimilars Sales Market Share, 2017-2028
Figure 44. Turkey Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Raibizumab Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 48. Global Raibizumab Biosimilars Production Capacity (K Units), 2017-2028
Figure 49. The Percentage of Production Raibizumab Biosimilars by Region, 2021 VS 2028
Figure 50. Raibizumab Biosimilars Industry Value Chain
Figure 51. Marketing Channels
